BioNTech to Acquire CureVac in US$1.25 Billion All-Stock Transaction

Retrieved on: 2025-06-16 00:06:24

Tags for this article:

Law firms of the Netherlands

Loyens & Loeff

Pfizer-BioNTech COVID-19 vaccine

Limited liability partnership

SKADDEN, ARPS, SLATE, MEAGHER & FLOM

Click the tags to see associated articles and topics

BioNTech to Acquire CureVac in US$1.25 Billion All-Stock Transaction. View article details on hiswai:

Excerpt

Covington & Burling LLP, Hengeler Mueller Partnerschaft von Rechtsanwälten mbB and Loyens & Loeff N.V. have advised BioNTech. BioNTech… Standard 1 ...

Article found on: globallegalchronicle.com

View Original Article